Raloxifene Hydrochloride For Breast Cancer Osteoporosis

Raloxifene Hydrochloride For Breast Cancer Osteoporosis

химическое название и суффикс, указывающие на то, что эта форма стероида и полового гормона представляет собой тип спирта, содержащего две гидроксильные группы

Описание:

Raloxifene Hcl is in a class of medications called selective estrogen receptor modulators (СЭРМ). acts as

an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. Raloxifene Hcl have efficacy against estrogen-sensitive cancers.

Raloxifene Hcl is an estrogen agonist antagonist, referred to as a selective estrogen receptor modulator and belongs to the benzothiophene class of compounds. The Raloxifene Hcl biological actions are largely mediated through binding to estrogen receptors, and it binding results in activation of estrogenic pathways in some tissues Agonism and and the blockade of estrogenic pathways in Antagonism.

заявка:

1. OverView:
Evista (ралоксифена гидрохлорид) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (СЭРМ) and belongs to the benzothiophene class of compounds. The biological actions of Raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (Agonism) and and the blockade of estrogenic pathways in other tissues (Antagonism).

2. Why is this medication prescribed:

(1) Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause (change of life; end of menstrual periods). Raloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue) in women who are at high risk of developing this type of cancer or who have osteoporosis. Raloxifene cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition.
(2) Raloxifene also cannot be used to decrease the risk of developing non-invasive breast cancer. Raloxifene is in a class of medications called selective estrogen receptor modulators (СЭРМ). Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.

3. Use and Dose:
Evista is specifically approved for the treatment and prevention of osteoporosis in postmenopausal women, the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. Evista is supplied as a 60 mg tablet designed for oral administration. The recommended initial dose of the drug is one 60 mg tablet daily, which may be administered any time of day without regard to meals.